SORC-13 is under clinical development by Soricimed Biopharma and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase I drugs for Epithelial Ovarian Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SORC-13’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SORC-13 overview
SORC-13 is under development for treatment of advanced refractory solid tumors such as epithelial ovarian cancer, colon cancer, non-small cell lung cancer, breast cancer, peritoneal cancer, esophageal cancer, uterine cancer, gastrointestinal stromal tumor, prostate cancer, parotid cancer, head and neck cancer, nasopharyngeal cancer, adenoid cystic cancer and pancreatic ductal adenocarcinoma and also for Coronavirus Disease 2019 (COVID-19). The drug candidate is administered as an intravenous infusion. It comprises of a bi-functional parent peptide called soricidin obtained from the shrew venom. The drug candidate targets TRPV6 ion channel.
Soricimed Biopharma overview
Soricimed Biopharma formerly BioProspecting NB, operates as a drug and diagnostic developer that offers pain management solutions. The company offers services such as development and commercialization of therapeutic and diagnostic programs. Its oncology management platform arises from the ability of soricidin and the C-series peptides to modulate the activity of a calcium ion channel. Soricimed Biopharma’s products are used in the treatment of breast cancer, ovarian cancer, and prostate cancer, and other cancer types. It operates through a network of contract research organizations that provide research outside its core capacities. Soricimed Biopharma is headquartered in Moncton, New Brunswick, Canada.
For a complete picture of SORC-13’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
